Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Neutral 0

Is Moderna (MRNA) Pricing Make Sense After 77% One-Year Surge And DCF Signal?

📉 Moderna's stock price has surged 77.3% over the last year but closed at $48.69 today after recent declines.

💸 The company recently reported a loss of approximately US$2.19b in free cash flow over the last twelve months.

🧮 A Discounted Cash Flow (DCF) model estimates Moderna's intrinsic value at US$22.87 per share.

⚠️ Based on the DCF analysis, Moderna appears to be overvalued by 112.9% compared to its current share price.

💹 The stock trades at a Price-to-Sales (P/S) ratio of 9.93x, which is higher than the company's proprietary Fair Ratio of 1.31x.

🏆 Moderna's P/S sits below the Biotechs industry average but remains above its specific peer group average.

📊 Simply Wall St identifies two contrasting investor narratives regarding Moderna's future fair value and risks.

💡 One optimistic narrative suggests a high fair value of US$175.00 based on potential pipeline success.

🐀 Another cautious narrative implies a low fair value near US$12.00 due to competitive pressure and regulatory concerns.

🦠 The cautious view highlights risks from reliance on specific vaccines and potential pricing policy changes.

🔬 The optimistic view emphasizes the company's mRNA pipeline, AI integration, and government contract opportunities.

📉 Both narratives agree that current sentiment is sharply divided regarding Moderna's post-pandemic value proposition.

🔄 The DCF model uses a two-stage free cash flow to equity method to project positive cash flows by 2030.

🏢 Simply Wall St rates Moderna just 1 out of 6 on their internal valuation checks indicating red flags.

Bullish Signals
  • Moderna has gained 57.8% year to date and 77.3% over the last year, demonstrating significant recent momentum despite short-term declines.
  • The company trades on a P/S ratio of 9.93x, which is below the Biotechs industry average of 10.95x, suggesting room for multiple expansion relative to the broader sector.
  • A bullish narrative estimates fair value at US$175.00, implying approximately 72.2% undervaluation compared to the recent share price of US$48.69.
  • Moderna is viewed as a biotech company with many pipeline products already in motion and potential upside if even a handful of programs succeed.
  • The company emphasizes its clean balance sheet while trading below book value, supported by years of reinvestment into its pipeline.
  • Cost cuts, AI use, and government contracts are highlighted as positive catalysts that could support an expanding mRNA pipeline.
  • Moderna's DCF model projects Free Cash Flow turning to about US$241.7m by 2030, indicating strong long-term cash generation potential once the transition from losses is complete.
  • The company frames the post-pandemic share price pullback as an overreaction to declining COVID revenues, suggesting a re-rating opportunity if future pipelines succeed.
  • Simply Wall St offers two leading Narratives for Moderna, with one bullish scenario projecting revenue growth of 48.43% and fair value at US$175.00.
Risk Factors
  • Moderna reported a twelve-month loss of US$2.19 billion in Free Cash Flow, with analysts projecting continued negative cash flow for several years.
  • According to the Discounted Cash Flow model, Moderna's stock is estimated to be 112.9% overvalued relative to its intrinsic value of US$22.87 per share against a recent price of US$48.69.
  • The company trades at a Price-to-Sales ratio of 9.93x, which exceeds the proprietary Fair Ratio of 1.31x suggested by Simply Wall St's valuation model.
  • A significant portion of community narratives highlight risks including reliance on a few key vaccines, potential regulatory scrutiny, and pricing policy constraints.
  • Concerns are raised regarding the need for external partners to fund high-cost programs, suggesting capital efficiency issues and dependency on third parties.
  • Competitive pressure and shifting regulatory landscapes are explicitly cited as headwinds that could impact future growth prospects.
  • The stock has experienced a 10.8% decline over the last 7 days and a 3 year return decline of 63.5%, indicating recent price volatility and long-term underperformance.
Full Analysis
Moderna's shares recently closed at US$48.69, reflecting a significant one-year surge of 77.3% despite recent declines of 10.8% in the last week and 1.8% over the past month. While year-to-date gains stand at 57.8%, longer-term returns have softened to a 63.5% decline over three years and a 73.8% drop over five years, though these multi-year metrics appear contradictory in the source text regarding directionality versus magnitude. Investors are currently divided on whether the stock's valuation aligns with its future prospects, leading Simply Wall St to assign it a score of just 1 out of 6 on its internal valuation checks. A Discounted Cash Flow (DCF) model projecting Free Cash Flow losses until 2030 estimates an intrinsic value of US$22.87 per share, implying the stock is currently trading at approximately 112.9% above this calculated fair value. Beyond cash flow metrics, valuation analysis using the Price-to-Sales (P/S) ratio indicates Moderna trades at a P/S multiple of 9.93x. This figure is lower than the broader biotechnology industry average of 10.95x but significantly higher than the peer group average of 5.47x and the platform's proprietary Fair Ratio of 1.31x, which adjusts for specific growth and risk characteristics. Despite these quantitative signals suggesting overvaluation, community narratives on the platform highlight a wide range of potential fair values based on differing assumptions about future revenue growth, ranging from as low as US$12.00 to as high as US$175.00. One optimistic narrative projects revenue growth at 48.43%, valuing the stock at US$175.00 which represents a potential undervaluation of 72.2% from recent close, while framing the post-pandemic pullback as an overreaction to declining COVID-19 revenues and highlighting a clean balance sheet alongside pipeline diversification. Conversely, a more cautious narrative accepts revenue growth assumptions around 17.91% and acknowledges risks such as competitive pressure, regulatory scrutiny, and pricing policy headwinds, which results in an implied fair value close to current trading levels with only about 5.6% overvaluation suggested. This divergence underscores the challenge of valuing Moderna without attaching a specific story to its long-term prospects beyond the pandemic vaccine boom. The article concludes by noting that while quantitative models like DCF and adjusted P/S ratios point towards potential overvaluation, investor sentiment remains mixed as they watch how Moderna's pipeline evolves and whether new partnerships can offset regulatory and competitive risks in the biotech space.